BIOMARKERS VALIDATION LABORATORIES

生物标志物验证实验室

• 批准号: 6133300
• 负责人: DAVID S. CHIA
• 金额: $ 29.6万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-16 至 2005-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6133300
• 关键词: biomarker; cancer registry /resource; carcinogenesis; chromosome aberrations; clinical research; cytogenetics; enzyme linked immunosorbent assay; flow cytometry; gene expression; genetic polymorphism; high throughput technology; human subject; immunocytochemistry; in situ hybridization; microarray technology; neoplasm /cancer genetics; tissue resource /registry; tumor antigens; western blottings

The goals for the Biomarker Validation Laboratory-called the UCLA Defined Tumor-Marker Core (D-TEC)-are to: 1. Optimally coordinate a consortium of currently operational laboratories for the direct purpose of evaluating and analyzing any and all identified markers of tumorigenesis. These laboratories include: Human Tissue Research Center (tissue procurement, sectioning, and histology), Tissue Analysis Laboratories (conventional immunohistochemistry, in situ hybridization, high throughput tissue microarray), Molecular Pathology Laboratories (gene expression, chromosomal abnormalities, polymorphism, high throughput array-based mutation analysis), Immunoassay Laboratory (ELISA, Western blot analysis), and Cellular Analysis Laboratories (flow cytometry, cytology, chromosomal analysis, cytogenetics) These laboratories are all in the UCLA School of Medicine (the Department of Pathology and Laboratory Medicine, the Department of Human Genetics, and the Jonsson Comprehensive Cancer Center) and therefore, have an established interaction and collaboration. 2. Coordinate the infrastructure for a thoughtful, yet rapid and flexible mechanism for study design, implementation, data collection, and information analysis. This infrastructure consists of distinguished faculty at UCLA which includes: the Core Laboratory Directors, an Internal Advisory Board committed to assisting in project design and strategic planning, and Bioinformatics core with combined expertise in biostatistics, bioinformatics, and data analysis and mining, and a Pathology Consultation Core for correlation of pathology diagnosis with a marker expression. 3. Establish a "Development Study" which will specifically focus on the production of tumor- specific tissue arrays to be used as one of the high throughput techniques for tumor marker evaluation.

生物标志物验证实验室的目标将UCLA定义的肿瘤标志物核心（D-TEC）归为：1。最佳协调当前运营实验室的财团，以直接评估和分析所有已识别的肿瘤结构标记。 These laboratories include: Human Tissue Research Center (tissue procurement, sectioning, and histology), Tissue Analysis Laboratories (conventional immunohistochemistry, in situ hybridization, high throughput tissue microarray), Molecular Pathology Laboratories (gene expression, chromosomal abnormalities, polymorphism, high throughput array-based mutation analysis), Immunoassay Laboratory (ELISA, Western blot分析）和细胞分析实验室（流式细胞术，细胞学，染色体分析，细胞遗传学）这些实验室都在UCLA医学院（病理学和实验室医学系，人类遗传学和琼斯森综合癌症中心），因此有建立的互动和协作。 2。协调基础架构，以实现研究，实施，数据收集和信息分析的周到，快速而灵活的机制。 该基础设施由加州大学洛杉矶分校的杰出教师组成，其中包括：核心实验室主管，一个内部咨询委员会，致力于协助项目设计和战略计划，以及生物信息学核心，具有生物统计学，生物信息学和数据分析和采矿方面的综合专业知识，以及用于与病理学的病理学核心核心诊断。 3.建立一项“开发研究”，该研究将特别集中在肿瘤特异性组织阵列的产生上，以用作肿瘤标记评估的高通量技术之一。